NEW YORK, April 6 (GenomeWeb News) - Ardais today said that it has extended a research collaboration with Aventis that the companies began in 2002.
Under the terms of the original collaboration, Aventis was granted access to Ardais' BIGR (Biomaterials and Information for Genomic Research) library of clinical data and biomaterials. Under the expanded agreement, Ardais will use this platform in combination with immunohistochemistry profiling "to assess the potential of certain biological targets in the pharmaceutical company's R&D pipeline."
Ardais said it would use its technology to optimize validation assays and assist in the characterization of targets in panels of normal and diseased human tissues.
Financial terms of the agreement were not disclosed.